BeOne’s next-gen BCL2 inhibitor wins FDA approval, taking aim at Venclexta

BeOne Medicines has received accelerated approval from the FDA for its next-generation BCL2 inhibitor, sonrotoclax, aimed at treating a rare and aggressive form of blood cancer. This approval positions sonrotoclax as a competitor to AbbVie and Genentech's Venclexta, which is currently used off-label for the same condition.